HF
AVTX icon

HRT Financial’s Avalo Therapeutics AVTX Stock Holding History

HRT Financial’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$718K Buy
+48,105
New +$752K ﹤0.01% 2267
2025
Q2 		– Sell
-10,289
Closed -$82K – 2592
2025
Q1 		$82K Sell
10,289
-29,711
-74% -$225K ﹤0.01% 2178
2024
Q4 		$297K Buy
+40,000
New +$428K ﹤0.01% 1722
2023
Q3 		– Sell
-55
Closed -$4K – 2388
2023
Q2 		$4K Buy
+55
New +$37K ﹤0.01% 2240
2021
Q4 		– Sell
-34
Closed -$210K – 3170
2021
Q3 		$210K Buy
+34
New +$276K ﹤0.01% 2653

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HRT Financial's AVTX Position: Q1 2026 in Review

HRT Financial opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 48,105 shares worth $718K. The stake represents ﹤0.01% of the portfolio and ranks #2267 among its holdings. This is a return to the name: HRT Financial previously reported a position in AVTX as recently as Q1 2025.

HRT Financial first reported a position in AVTX in Q3 2021 and has held it in 5 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • HRT Financial held 48,105 shares of Avalo Therapeutics worth $718K as of Q1 2026.
  • Avalo Therapeutics was a new HRT Financial position in Q1 2026.
  • Avalo Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2267 holding.
  • HRT Financial first reported a position in Avalo Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.